Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsRaw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tg Therapeutics (TGTX) Accounts Payables (2016 - 2025)

Historic Accounts Payables for Tg Therapeutics (TGTX) over the last 10 years, with Q3 2025 value amounting to $112.3 million.

  • Tg Therapeutics' Accounts Payables rose 1077.74% to $112.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $112.3 million, marking a year-over-year increase of 1077.74%. This contributed to the annual value of $58.3 million for FY2024, which is 5153.23% up from last year.
  • As of Q3 2025, Tg Therapeutics' Accounts Payables stood at $112.3 million, which was up 1077.74% from $134.0 million recorded in Q2 2025.
  • Tg Therapeutics' 5-year Accounts Payables high stood at $134.0 million for Q2 2025, and its period low was $29.7 million during Q3 2022.
  • In the last 5 years, Tg Therapeutics' Accounts Payables had a median value of $51.3 million in 2021 and averaged $66.1 million.
  • Per our database at Business Quant, Tg Therapeutics' Accounts Payables crashed by 3350.19% in 2022 and then soared by 15516.97% in 2024.
  • Quarter analysis of 5 years shows Tg Therapeutics' Accounts Payables stood at $51.3 million in 2021, then fell by 18.08% to $42.0 million in 2022, then decreased by 8.44% to $38.5 million in 2023, then skyrocketed by 51.53% to $58.3 million in 2024, then skyrocketed by 92.7% to $112.3 million in 2025.
  • Its last three reported values are $112.3 million in Q3 2025, $134.0 million for Q2 2025, and $133.9 million during Q1 2025.